Quantitative Image Biomarkers
It is of paramount importance that biomarker measurements are highly reproducible and sensitive enough to detect relevant changes that may have clinical repercussions, and this type of measurement cannot be obtained visually
Dr. Max Wintermark, M.D.Professor of Radiology & Chief of Neuroradiology Stanford University Medical Center
Neurocloud is a unique comprehensive tool for PET, SPECT and MRI that
- increases diagnostic confidence and the value of the specialist’s work
- simplifies collaborative work between clinical specialists in nuclear medicine, radiology and neurology, providing objective and quantitative measurements with clinical validation
With Neurocloud you can
- Immediately locate abnormal areas of your patients’ brains
- Quantify hypo and hypermetabolisms with high sensitivity
- Determine if gray or white matter atrophy is within the expected range for your patient’s age
- Explore images and analysis results with an advanced online viewer
- Share results and make customized reports
- Quantitative monitoring of the evolution of neurodegenerative diseases
Dra. Puy Garrastachu considers that Neurocloud is a support tool in the evaluation of inconclusive PET images, being in our daily experience, useful in cases of atypical parkinsonism and dementia of difficult diagnosis.
The H. del Mar Epilepsy Unit is a European Reference Center in the diagnosis and treatment of refractory epilepsy. They have decided to use all the applications of Neurocloud since it allows them to easily integrate nuclear medicine and magnetic resonance studies and facilitate their work as a team.
Dr. Xavier Setoain, co-author of the epileptogenic focus location method implemented by Neurocloud-SISCOM, uses it routinely because of the ease of use and the confidence provided by the results it provides.
Dr. Carlos Torrijo has been using Neurocloud for years as a quantification assistant for the neurology studies he carries out with PET 18FDG. Recently he has supervised an end of course work where he has compared the diagnostic performance of Neurocloud-PET in 50 dementia patients, finding that in 38% of the cases the use of Neurocloud improved the diagnosis and the confidence of the reporting physician.